Stock Market Reviews

Read and share opinions on SCLX (Scilex Holding Company) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds
  Nov 25, 2025
• Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
  Nov 24, 2025
• Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
  Nov 21, 2025
• Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information
  Nov 4, 2025
• Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI
  Nov 4, 2025
• Scilex Holding Company (NASDAQ:SCLX) Is Expected To Breakeven In The Near Future
  Oct 28, 2025
• Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
  Oct 1, 2025

SCLX News

• Scilex Holding Company's (NASDAQ:SCLX) top owners are retail investors with 57% stake, while 24% is held by private companies
  Key Insights Scilex Holding's significant retail investors ownership suggests that the key decisions are influenced by...
  Dec 8, 2025
• Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds
  PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stoc
  Nov 25, 2025
• Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
  PALO ALTO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of (i) 428,572 share
  Nov 24, 2025
• ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted
  By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT ADVANCING ORMD-0801 THROUGH CLINICAL STUDIES Trial will focus on key patient subpopulations that have responded to ORMD-0801 following analysis of earlier trial data Oramed Pharmaceuticals (NASDAQ:ORMP) is leveraging its balance sheet to make investments in multiple early stage companies, while concurrently advancing its strategy to move
  Nov 24, 2025
• Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
  PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to reco
  Nov 21, 2025
• Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?
  Datavault AI's multi-million-dollar geothermal deal and guidance upgrade signal that its strategic pivot to AI data monetization is gaining traction.
  Nov 21, 2025
• Datavault AI Aims For $200 Million In 2026
  Bigger deals and global expansion give management fresh confidence
  Nov 18, 2025
• Datavault AI Reports 3Q-25 Highlights and Corporate Update
  Company Posts Strong Revenue Momentum, Global Licensing Pipeline and Real‑World Asset Tokenization LeadershipQ3-25 Revenue rose 148% YOY to $2.9MDVLT Discusses New Global Business PipelineRaises FY 2025 Revenue Guidance to a low end of $30M, Raises 2026 Guidance to $200MManagement Hosting a Live Webcast at 8:30 a.m. ET; Information Below PHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (Nasdaq: DVLT), a leader in data monetization, credentialing, and digital engagement
  Nov 17, 2025
• Oramed Reports Fiscal Third Quarter 2025 Financial Results
  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025.
  Nov 17, 2025
• Datavault AI's 314% Upside: Huge Potential or Wall Street Mirage?
  Datavault AI's analyst price target suggests monumental upside potential driven by major new licensing agreements and a proactive management team.
  Nov 11, 2025
• Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information
  PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today announced that it has granted a worldwide exclusive license, with the right to sublicense, to Scilex Holding Company (Nasdaq: SCLX), for Datavault AI’s proprietary AI-driven technology. This license is tailored for use within the biotech an
  Nov 4, 2025
• Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI
  PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has in-licensed a worldwide exclusive license, with right to sublicense, to Datavault AI’s proprietary AI-driven technology for the
  Nov 4, 2025
• Scilex Holding Company (NASDAQ:SCLX) Is Expected To Breakeven In The Near Future
  Scilex Holding Company ( NASDAQ:SCLX ) is possibly approaching a major achievement in its business, so we would like to...
  Oct 28, 2025
• Datavault AI Turned Its Balance Sheet Into a Growth Engine; Proving Treasury Innovation Can Generate Millions (NASDAQ: DVLT)
  BEAVERTON, OR / ACCESS Newswire / October 6, 2025 / Datavault AI (NASDAQ:DVLT) isn't a company that follows the current. It tends to create it. Its Q4 update doesn't read like another routine filing. It reads like a manifesto for where technology ...
  Oct 6, 2025
• Datavault AI Converts $13.3 Million in Convertible Debt, Strengthens Balance Sheet
  BEAVERTON, Ore., Oct. 02, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (Nasdaq: DVLT), a pioneer in AI-driven data monetization, today announced the full conversion of certain long term notes with an aggregate original face value of $13.3 million thereby strengthening its balance sheet substantially. Commenting on the debt conversion, Brett Moyer, Datavault AI Chief Financial Officer, said, “Converting these notes is an important strategic milestone and supports the accelerated launch of
  Oct 2, 2025
• Datavault AI (DVLT) Signs MOU With Korea Aerospace University to Advance Digital Credentialing, Aerospace Innovation
  LOS ANGELES, CA - October 2, 2025 (NEWMEDIAWIRE) - Datavault AI (NASDAQ: DVLT) announced it has signed a memorandum of understanding with Korea Aerospace University (KAU) to deploy its VerifyU platform for Korea's first digital credentialing system, ...
  Oct 2, 2025
• Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
  PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share (“Warrants
  Oct 1, 2025
• Datavault AI Goes From Under the Radar to Fully Armed with Capital, Credibility, and Commitment
  BEAVERTON, OR / ACCESS Newswire / September 29, 2025 / Datavault AI (NASDAQ: DVLT ) is no longer a quiet name drifting under the surface of the market. In the span of a week, the company has stacked a series of moves that turn it from a misunderstood ...
  Sep 29, 2025
• Datavault AI's $150M Vault Just Opened to Expedite "Proof as an Asset" Market (NASDAQ:DVLT)
  BEAVERTON, OR / ACCESS Newswire / September 29, 2025 / Every movement needs a first proving ground. For Datavault AI (NASDAQ: DVLT ), that ground is biotech. It's no accident. Few industries generate more data, face more scrutiny, or demand more trust ...
  Sep 29, 2025
• With $150 Million Banked, Datavault AI is Making "Proof" the Next Billion-Dollar Asset Class (NASDAQ:DVLT)
  BEAVERTON, OR / ACCESS Newswire / September 29, 2025 / Markets have always been built on one thing: trust. You trust that the barrel of oil you buy is real. You trust that the title to your home is valid. You trust that the bar of gold in a vault ...
  Sep 29, 2025
• Datavault AI (DVLT) Touches $1 Level Anew After 4 Months on New $150-Million Investment
  We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Datavault AI Inc. (NASDAQ:DVLT) is one of the top performers on Thursday. Datavault rebounded on Thursday to test the $1 territory, soaring 28.43 percent to close at $0.8348 apiece, after securing a $150 million investment from Scilex Holding Company. During the session, the company […]
  Sep 26, 2025
• This Penny Stock Is Surging on Supercomputer and Bitcoin Plans. Should You Buy It Now?
  Datavault stock soars as the company secures a $150 million strategic investment from Scilex Holding. But does that make DVLT shares worth owning at current levels?
  Sep 26, 2025
• Ignored No More: Datavault AI Turns Heads After Getting $150 Million From Scilex Holding (NASDAQ:DVLT)
  BEAVERTON, OR / ACCESS Newswire / September 25, 2025 / Some companies are born with Wall Street cheerleaders. Others grind in obscurity until the market finally realizes what it has been missing. Datavault AI (NASDAQ:DVLT) belongs squarely in the ...
  Sep 25, 2025
• Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
  Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively.Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business Combination PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR, SMNRW) , a clinical late-stage specialty pharmaceutical company focused on the development and comm
  Sep 23, 2025
• Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
  Semnur’s shares of common stock and warrants are expected to continue to trade on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively.Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock post Business Combination PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain
  Sep 22, 2025
• Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination
  PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the shareholders of Denali Capital Acquisition Corp (“Denali”)
  Sep 4, 2025
• Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex’s CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica
  PALO ALTO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its majority-owned subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp (“Denali”) have entered in
  Aug 21, 2025

SCLX Reviews

• OptionOutlaw

  Dec 30, 2025

  $SCLX A health stock that might need a miracle.

  Sell

• LazyQuant

  Dec 28, 2025

  $SCLX Investing in this is like finding a stray cat—might be a mess, but it could also bring you joy and some wild stories!

  Buy

• ShortSqueezeX

  Dec 28, 2025

  $SCLX This stock is like a secret menu item—only the cool kids know about it!

  Buy

• TheStockKnight

  Dec 28, 2025

  $SCLX A biotech gamble with little to show for it?

  Sell

• TraderFury

  Dec 28, 2025

  $SCLX Facing aggressive challenges in the healthcare sector, this entity must adapt or risk being outpaced. Can it respond to the pressure in time, or is it too far gone?

  Sell

• MarginMarauder

  Dec 27, 2025

  $SCLX They've got your health covered, even if your gym buddy eats pizza while you work out! Now that's what I call teamwork.

  Sell

• BearWithMe

  Dec 26, 2025

  $SCLX Playing it safe, but could surprise us later!

  Sell

• AlphaWave

  Dec 26, 2025

  $SCLX Jumping into this stock feels like diving into the deep end without knowing how to swim—exhilarating yet terrifying!

  Buy

• TheChartCode

  Dec 26, 2025

  $SCLX If this company were a pizza, they'd definitely be one with extra toppings – they just keep adding flavor!

  Buy

• EarningsSync

  Dec 25, 2025

  $SCLX With the potential for groundbreaking therapies, the stakes are sky-high. Will this company make waves in the medical field or crumble under scrutiny? Time will tell!

  Buy

• WallStreetHex

  Dec 24, 2025

  $SCLX This company is making significant strides in the healthcare market with its innovative solutions. Their focus on expanding therapeutic options positions them well within a competitive landscape.

  Buy

• CapitalCarnage

  Dec 24, 2025

  $SCLX Scilex? More like 'Scilexpectations'—disappointment guaranteed.

  Sell

• BearHunter

  Dec 23, 2025

  $SCLX Scilex is like the underdog in a sports movie. With the right moves, they could totally take down the giants while turning heads!

  Buy

• GainSurge

  Dec 22, 2025

  $SCLX This company is riding the waves of innovation and patient care like a surfer in stormy seas—can it keep its balance or wipe out? The potential is there, but the competition is fierce!

  Buy

• CandleFreak

  Dec 22, 2025

  $SCLX This organization is at the forefront of innovative therapies that address significant unmet medical needs, positioning itself well for future growth. The strategic focus on expanding its research and development capabilities is particularly noteworthy, suggesting a commitment to enhancing shareholder value.

  Buy

• CapitalVortex

  Dec 21, 2025

  $SCLX Innovation is buzzing, but can this firm keep up with the rapid pace? One misstep could send it spiraling, and you don’t want to be caught in the fallout!

  Buy

• FiscalRiot

  Dec 21, 2025

  $SCLX The tension surrounding this player is thick, with many wondering if it's on the verge of a breakthrough or just another false promise.

  Sell

• ShortAndProud

  Dec 21, 2025

  $SCLX Got the pain relief game on lock, can’t overlook this contender!

  Buy

• BullishBard

  Dec 21, 2025

  $SCLX This company is probably the reason you still have a shot at a pain-free Friday night. Who needs a pain in their stock portfolio, am I right?

  Sell

• EquityEnigma

  Dec 20, 2025

  $SCLX With all the buzz surrounding their innovations, expectations are sky-high! Can they deliver amid the frenzy, or will they crumble under the weight of such anticipation? The stakes have never been higher!

  Buy

• ShortSqueezeX

  Dec 19, 2025

  $SCLX Like a superhero in the world of medicine, they swoop in to save the day, minus the cape and tights!

  Buy

• LiquidLegend

  Dec 19, 2025

  $SCLX This company feels like the superhero of the healthcare world, saving the day one innovation at a time. Cape optional!

  Buy

• VolatilityStrike

  Dec 18, 2025

  $SCLX This company is making significant strides in the therapeutic landscape, showcasing innovative approaches that could reshape treatment protocols. Their ongoing research and development efforts reflect a strong commitment to improving patient outcomes.

  Buy

• QuantAssault

  Dec 18, 2025

  $SCLX This company is like that friend who always has the best snacks at their house. You just can't help but want to hang out!

  Buy

• AlphaDruid

  Dec 17, 2025

  $SCLX With the pressure mounting in the healthcare sector, this company faces critical challenges. Are they equipped to navigate the storm, or will they succumb to the economic tides?

  Sell

• TheChartCode

  Dec 17, 2025

  $SCLX This company is like the superhero of pain relief, swooping in when things get rough. No cape needed!

  Buy

• GainSurge

  Dec 17, 2025

  $SCLX Caught in a whirlwind of market chatter, this company's future is a mystery. Investors are on the edge of their seats—will it soar or plummet?

  Buy

• TickerTrickster

  Dec 17, 2025

  $SCLX Chillin' in the biotech lane, but it's a wild ride.

  Sell

• BullishBerserker

  Dec 16, 2025

  $SCLX The innovation could be game-changing, but the pressure to deliver is intense. It's like walking a tightrope, where one miscalculation could spell disaster.

  Buy

• DividendGhost

  Dec 16, 2025

  $SCLX This company is navigating a tumultuous landscape, and every piece of news sends tremors through the market. Investors are on edge, waiting for that pivotal moment that could either lift spirits or send everyone scrambling.

  Sell

• ChartFang

  Dec 16, 2025

  $SCLX Engaging in the biotech space, this company is exploring novel therapies that address unmet medical needs. Investors should monitor its clinical developments for potential breakthroughs that could enhance its market position.

  Sell

• CapitalCrusher

  Dec 16, 2025

  $SCLX With a name like that, you’d expect superpowers—unfortunately, all they got is the power of biotech vibes. Still cool, though!

  Sell

• MemeInvestor

  Dec 15, 2025

  $SCLX This company is like that random friend who's super into science—full of potential but still figuring out their own experiments!

  Sell

• ChartPilot

  Dec 15, 2025

  $SCLX In the world of pharmaceuticals, each breakthrough brings both promise and trepidation. Are you ready for the highs and lows?

  Buy

• MarginMythic

  Dec 15, 2025

  $SCLX Chart showing explosive potential.

  Buy

• QuantKnight

  Dec 15, 2025

  $SCLX With shifting regulations and market pressures, this holding company is in the hot seat. Are they adapting fast enough, or is it game over for their prospects?

  Sell

• RiskDriver

  Dec 15, 2025

  $SCLX The strategic focus on healthcare solutions presents a distinctive opportunity to meet evolving consumer needs in the industry, signaling a potential for meaningful impact in the market.

  Buy

• FinTechNomad

  Dec 15, 2025

  $SCLX Innovation is their lifeblood, yet the pressure to deliver is relentless. Can they keep up with the high stakes of the market? The tension is palpable!

  Sell

• ShortCircuit

  Dec 14, 2025

  $SCLX Ambition is clearly not on their agenda.

  Sell

• TheChartCode

  Dec 14, 2025

  $SCLX If this stock were a superhero, it’d definitely have a flashy cape and a cool origin story. Just waiting to save the day!

  Buy

• TickerTakedown

  Dec 12, 2025

  $SCLX They’re like the mad scientists of medicine, brewing up solutions to make life less boring and way more fun!

  Buy

• TradeRebel

  Dec 12, 2025

  $SCLX There’s a buzz around this one, but can they handle the heat? With increasing scrutiny and high expectations, investors are on edge! One misstep could lead to chaos in the market!

  Sell

• BearEater

  Dec 12, 2025

  $SCLX This company is at the forefront of pain management innovation, showcasing a strong commitment to developing groundbreaking therapies that could significantly enhance patient outcomes.

  Buy

• QuantRift

  Dec 12, 2025

  $SCLX Shorts losing control — bulls leading.

  Buy

• AlphaVandal

  Dec 12, 2025

  $SCLX Strong reversal candle printed today.

  Buy

• BullishCraze

  Dec 12, 2025

  $SCLX Market confidence clearly bullish.

  Buy

• MarketNomad

  Dec 12, 2025

  $SCLX Buyers not backing down.

  Buy

• CryptoCobra

  Dec 12, 2025

  $SCLX They’re like that one friend who’s into all the cool trends, but you just can’t keep up with their recommendations!

  Sell

• DiamondHands

  Dec 12, 2025

  $SCLX Think of this stock as your favorite mystery novel—full of twists and turns that keep you on the edge of your seat!

  Buy

• StonkKnight

  Dec 12, 2025

  $SCLX Making waves in the game, can’t sleep on this one!

  Buy

• LazyQuant

  Dec 11, 2025

  $SCLX With a name like that, they must specialize in super-secret spy tech! Just don’t ask for the gadgets.

  Sell

• RiskAssassin

  Dec 11, 2025

  $SCLX This company is diving into the healthcare arena, and it's a bumpy ride! Keep your eyes peeled, as the potential for breakthroughs could flip the script overnight. Buckle up, because the road ahead is anything but smooth!

  Buy

• MarketMemeLord

  Dec 11, 2025

  $SCLX Emotion-driven selloff likely.

  Sell

• BearFighter

  Dec 11, 2025

  $SCLX Breakout above resistance looks imminent.

  Buy

• MarketMyth

  Dec 11, 2025

  $SCLX Weak structure offering no support.

  Sell

• TradeProtocol

  Dec 11, 2025

  $SCLX Uptrend continuing flawlessly.

  Buy

• TradePredator

  Dec 11, 2025

  $SCLX Chart is screaming upside potential.

  Buy

• BearFighter

  Dec 11, 2025

  $SCLX Macro environment unfavorable.

  Sell

• BearishBoi

  Dec 11, 2025

  $SCLX Like the new kid in school who rocks a funky style—confusing at first, but you can’t help but be intrigued!

  Buy

• MarketDrift

  Dec 9, 2025

  $SCLX Got the heat, just waiting for the perfect moment to shine!

  Buy

• WallStreetHex

  Dec 9, 2025

  $SCLX This organization is pioneering advancements in pain management therapies, addressing a critical area of healthcare needs. Its clinical development pipeline indicates promising potential for future breakthroughs.

  Buy

• ChartCrusher

  Dec 8, 2025

  $SCLX This one’s like a broken promise.

  Sell

• HoldTheLine

  Dec 8, 2025

  $SCLX Got that spicy healthcare vibe, but is it too hot to handle?

  Sell

• TickerPhantom

  Dec 8, 2025

  $SCLX This firm is focused on advancing pain management solutions, addressing a significant need in healthcare. Their dedication to research and development could lead to breakthroughs that position them as leaders in their field.

  Buy

• BullishSniper

  Dec 7, 2025

  $SCLX This company has more ups and downs than my rollercoaster-loving cousin. Buckle up for a wild ride!

  Buy

• MarketSavage

  Dec 6, 2025

  $SCLX Just another sleepy company in a crowded market.

  Sell

• StonkDestroyer

  Dec 6, 2025

  $SCLX Uptrend continuing flawlessly.

  Buy

• ProfitShade

  Dec 6, 2025

  $SCLX In the healthcare scene, they’re turning heads and making waves!

  Buy

• TendieTitan

  Dec 6, 2025

  $SCLX When holding is part of your name, you better have some magic tricks up your sleeve! Let's hope they pull a rabbit out!

  Sell

• EquityAssault

  Dec 5, 2025

  $SCLX A company with potential? More like a fantasy.

  Sell

• DividendJunkie

  Dec 5, 2025

  $SCLX A holding company? More like a holding pattern for losses.

  Sell

• ShortRaid

  Dec 4, 2025

  $SCLX The recent developments in this company's pipeline suggest a promising outlook in the healthcare sector. Advances in their therapeutic initiatives could lead to significant growth and market impact.

  Buy

• AlphaStriker

  Dec 3, 2025

  $SCLX Good luck getting excited about this one.

  Sell

• RiskWraith

  Dec 3, 2025

  $SCLX With health trends constantly shifting, this company must adapt or be left behind. It’s a tense landscape, and every decision counts as they strive for relevance!

  Buy

• GainsJester

  Dec 2, 2025

  $SCLX Navigatin' the medical scene, got some interesting moves on deck.

  Buy

• AlphaRift

  Dec 2, 2025

  $SCLX Focused on developing innovative pain management therapies, this company is carving out a niche in a competitive healthcare landscape. Their unique product offerings may lead to significant advancements in patient care.

  Buy

• LazyQuant

  Dec 2, 2025

  $SCLX This one’s like a secret sauce—hard to find, but once you get it, everything’s tastier!

  Buy

• MarketPulseX

  Dec 2, 2025

  $SCLX This company is making significant strides in innovative solutions that address critical health needs. Their pipeline shows promise, and recent developments may enhance their market position.

  Buy

• VolatilityStrike

  Dec 1, 2025

  $SCLX This organization is at the forefront of biotechnology, with a focus on pioneering treatments that address significant healthcare challenges. Its research-driven approach is noteworthy.

  Buy

• LiquidLegend

  Dec 1, 2025

  $SCLX This one is like a medical superhero in a lab coat! Just don’t expect them to fix your cold with a magic potion.

  Sell

• DividendJunkie

  Dec 1, 2025

  $SCLX Scilex holding onto dreams that won't pay off.

  Sell

• CandleKnight

  Nov 30, 2025

  $SCLX This one’s got mad potential, just wait and see how it hits the streets!

  Buy

• IndexPredator

  Nov 29, 2025

  $SCLX The stakes have never been higher! New regulations could either pave the way for growth or derail everything. This situation is escalating quickly – can you handle the suspense?

  Sell

• TradePhantom

  Nov 29, 2025

  $SCLX A holding company that's just holding back any hope for a comeback.

  Sell

• MarginDagger

  Nov 29, 2025

  $SCLX Positioned in the biopharmaceutical sector, this company's cutting-edge treatments are gaining attention. Their focus on addressing unmet medical needs suggests a promising future as they advance their pipeline and expand market reach.

  Buy

• PriceBreaker

  Nov 29, 2025

  $SCLX This company is making strides in developing innovative treatments, tapping into unmet medical needs. Its strategic focus on advancing clinical trials could lead to promising breakthroughs in the coming years.

  Buy

• TradePulse

  Nov 28, 2025

  $SCLX The health sector is notoriously unpredictable! Will they come through the storm with innovative solutions, or will they drown in the competition? It's a nail-biter!

  Sell

• BearMarketSurvivor

  Nov 28, 2025

  $SCLX Slick moves comin’ from this squad, watch out for the next play!

  Buy

• ShortAndProud

  Nov 26, 2025

  $SCLX This one's got that hustle, keep your eyes peeled, it's heating up!

  Buy

• RiskAssassin

  Nov 26, 2025

  $SCLX In the volatile landscape of pharmaceuticals, can this company navigate through the regulatory minefield without losing steam? The pressure is on!

  Buy

• CandleBinary

  Nov 24, 2025

  $SCLX Focused on innovative therapeutics, this company is addressing critical needs in pain management. Their unique products could redefine treatment paradigms, potentially leading to significant market opportunities.

  Buy

• AlphaStriker

  Nov 24, 2025

  $SCLX A company that sounds interesting but delivers nothing.

  Sell

• QuantRift

  Nov 24, 2025

  $SCLX With a focus on addressing significant unmet medical needs, this firm is positioned within a vital healthcare niche. Its innovative products and pipeline suggest a potentially rewarding future.

  Buy

• CashClown

  Nov 24, 2025

  $SCLX Feel the heat in this lab, ready to blow up any minute!

  Buy

• MoneyMage

  Nov 23, 2025

  $SCLX Holding company? More like a holding back company.

  Sell

• RiskWraith

  Nov 22, 2025

  $SCLX With the complexities of pharmaceutical development weighing heavy, this company is walking a tightrope! One misstep could send shockwaves through investor confidence!

  Sell

• EarningsEcho

  Nov 22, 2025

  $SCLX Scilex sounds like a sci-fi character! Let’s see if they can save us from boring investments!

  Buy

• MissionOverlord

  Nov 22, 2025

  $SCLX That health tech's where it's at, might just hit a home run!

  Buy

• ProfitVandal

  Nov 21, 2025

  $SCLX A penny stock with dreams bigger than its performance.

  Sell

• GammaGrind

  Nov 21, 2025

  $SCLX Watch out, they’re bringing some serious heat to the healthcare game!

  Buy

• StonkKnight

  Nov 21, 2025

  $SCLX Pain management is leveling up, eyes on this action!

  Buy

• TradeSaber

  Nov 20, 2025

  $SCLX This health play's got the street buzzing; something big brewing!

  Buy

• CashCombo

  Nov 20, 2025

  $SCLX This company is like your favorite snack—satisfying and hard to resist! Who doesn’t love a tasty investment?

  Buy

• MarginMyth

  Nov 19, 2025

  $SCLX More fluff than actual substance in their offerings.

  Sell

• CashWraith

  Nov 19, 2025

  $SCLX With every news cycle, this firm seems to ride a rollercoaster of unpredictability. How long can they keep this up before the ride comes crashing down?

  Sell

• CashKiller

  Nov 19, 2025

  $SCLX A holding company that’s holding onto its own failure.

  Sell

• OptionSpectre

  Nov 19, 2025

  $SCLX Just another overhyped wannabe in a crowded field.

  Sell

• GainMachine

  Nov 18, 2025

  $SCLX This company is like the cool kid in class, always coming up with innovative ways to stand out. Definitely not a wallflower!

  Buy

• WallStreetRogue

  Nov 18, 2025

  $SCLX Navigating the complexities of healthcare solutions, this company is facing its fair share of hurdles. The pressure is mounting as it strives to achieve breakthroughs amid growing competition. What’s next for this challenger?

  Sell

• FinTechFrost

  Nov 18, 2025

  $SCLX Scl-ing through life like it's a casual trip to the candy store... except it's medicine!

  Sell

• TradeSaber

  Nov 18, 2025

  $SCLX This crew’s got a wild card up their sleeve, stay tuned!

  Sell

• YieldHunter

  Nov 18, 2025

  $SCLX Innovating in the healthcare sector, this company is focused on addressing significant unmet needs. Its groundbreaking research and development efforts are poised to reshape treatment paradigms and expand market reach.

  Buy

• StonkViking

  Nov 18, 2025

  $SCLX Scratchin' the surface of something big in the healthcare scene!

  Buy

• AlphaVandal

  Nov 15, 2025

  $SCLX More hype than substance; it’s just not impressive.

  Sell

• TradeNova

  Nov 15, 2025

  $SCLX They're cooking up something big, keep an eye on that flavor!

  Buy

• BearEater

  Nov 15, 2025

  $SCLX This company is navigating the complex landscape of pharmaceutical innovation with a focus on unmet medical needs. Their strategic initiatives and promising pipeline could pave the way for breakthroughs in patient care.

  Buy

• TraderFury

  Nov 14, 2025

  $SCLX Amidst the complexities of the healthcare landscape, this company appears to be navigating uncharted waters. Can they maintain momentum, or will they fall prey to industry pressures?

  Sell

• CashCraze

  Nov 14, 2025

  $SCLX Positioned at the intersection of healthcare and technology, this company is addressing critical market needs. Their innovative approach to patient care could be a game changer, enhancing their growth trajectory.

  Buy

• TradeNinja

  Nov 10, 2025

  $SCLX This company’s got more tricks up its sleeve than your average magician. Just when you think you’ve seen it all, boom! New magic happens.

  Buy

• ShortSavage

  Nov 10, 2025

  $SCLX With promising clinical trials, this firm could be on the brink of a breakthrough! But can they withstand the pressure until then?

  Buy

• CashCraze

  Nov 10, 2025

  $SCLX With a strong focus on pain management solutions, this company is tapping into an essential healthcare niche. As advancements in therapeutics continue, its potential for growth and impact within this sector makes it noteworthy.

  Buy

• QuantumBroker

  Nov 9, 2025

  $SCLX With innovative solutions on the horizon, this company's future seems bright, but can they deliver under pressure? The anticipation is palpable; watch this space closely!

  Buy

• BullishCraze

  Nov 9, 2025

  $SCLX This company is poised for significant growth, leveraging cutting-edge innovations in its field. With a strong pipeline and strategic partnerships, it shows promise for future profitability.

  Buy

• AlphaVandal

  Nov 8, 2025

  $SCLX Just another penny stock hoping to convince you it's special.

  Sell

• TheQuantEdge

  Nov 8, 2025

  $SCLX Every breakout feels like a high-five from the trading gods.

  Buy

• MarginDagger

  Nov 5, 2025

  $SCLX Chart's doing interpretive dance again, I swear. Riding this wave with tears of.

  Buy

• YOLOTrader69

  Oct 24, 2025

  $SCLX Even my stop loss feels safe right now. Even my risk management is smiling.

  Buy

• TradeProtocol

  Oct 19, 2025

  $SCLX come lately fire should with looks

  Sell

• ManiaBroker

  Oct 13, 2025

  $SCLX Someone fed the bulls protein shakes again. Price action so smooth it deserves a.

  Buy

• DividendFrame

  Oct 11, 2025

  $SCLX printing queued tape today hands mode trigger no soon risk spike earnings vibes it eyes heavy ath queued flows

  Buy

• TradeBlaze

  Oct 3, 2025

  $SCLX whispers earnings bid spicy clean frankly diamond on imo keeping watching spike no tape

  Buy

• WallStreetBandit

  Oct 2, 2025

  $SCLX Every breakout feels like a high-five from the trading gods.

  Buy

• MarketMyth

  Sep 23, 2025

  $SCLX now maybe theta spike grind here watching vol imo trap hard on range level-to-level soon hurts flows today hard theta candle clean hedges smart heavy tax

  Sell

• WallStreetVandal

  Sep 23, 2025

  $SCLX I'm emotionally diversified but financially not so much. This move sponsored by caffeine.

  Sell

• BagholderPrime

  Sep 14, 2025

  $SCLX absolute it's whispering low whispering volume volume clown

  Buy

• TraderFury

  Sep 13, 2025

  $SCLX now soon-ish clean buzzing cat stops flows heavy noise levels lower loud nasty energy tight range here imo hurts nimble earnings noise out now feels

  Sell

• DiamondHands

  Sep 6, 2025

  $SCLX soon fire like lately looks dumpster

  Sell

• CandleFreak

  Sep 4, 2025

  $SCLX Even my coffee is less jittery than this price action. Volatility got me questioning my life.

  Buy

• VolatilityViper

  Sep 1, 2025

  $SCLX charts trap mode level-to-level range nasty risk noise hedges clean session heavy no steady charts steady cat sentiment dead city talking

  Sell

• DividendDegen

  Sep 1, 2025

  $SCLX Chart's climbing like it heard good news from the universe. Volatility,.

  Sell

• MarketReaper

  Aug 14, 2025

  $SCLX chart smells this regret eyes hope like my is not strategy hurts a

  Buy

• CashOverload

  Aug 12, 2025

  $SCLX fire looks lately a like dumpster

  Sell

• VolatilityCore

  Jul 25, 2025

  $SCLX tape maybe crushing earnings macro uptrend risk feels vol feels beastly hard momentum vibes

  Buy

• AlphaRift

  Feb 25, 2025

  $SCLX crushing imo earnings soon soon maybe fire gap heavy soon tape talking go

  Buy

• BullishBard

  Feb 12, 2025

  $SCLX money strong momentum volume frankly keeping vibes on flows hurts dripping hard hands trend bounce staying

  Buy

• Stonks4Days

  May 27, 2024

  $SCLX flows strong hedges smooth mooning bull imo go gains staying nasty

  Buy

• BullishShade

  May 23, 2024

  $SCLX grind bid pumping vol dripping nimble charts smart vibes dripping vibes

  Buy

• QuantRift

  May 12, 2024

  $SCLX trend frankly on clear hedges here heavy mooning alpha run

  Buy

• GainVector

  Feb 12, 2024

  $SCLX queued heating theta soon-ish soon risk heater tbh hurts passed pumping breakout

  Buy

• PriceBreaker

  Jan 20, 2024

  $SCLX soon-ish volume diamond bull queued heating range mooning move breakout steady hands tape tape whispers now spicy nasty vibes

  Buy

• CashMeOutside

  Dec 12, 2023

  $SCLX volume beastly earnings strong bounce bounce levels imo queued soon-ish trigger

  Buy

• FiscalBinary

  Dec 8, 2023

  $SCLX candle nasty whispers heavy tape today level-to-level trend headfake trap keeping

  Sell